{"nctId":"NCT04673214","briefTitle":"Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment","startDateStruct":{"date":"2020-12-16","type":"ACTUAL"},"conditions":["Covid19"],"count":114,"armGroups":[{"label":"Triple therapy","type":"EXPERIMENTAL","interventionNames":["Drug: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol"]},{"label":"Double therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Azithromycin / Ribaroxaban / Paracetamol"]}],"interventions":[{"name":"Azithromycin / Ivermectin / Ribaroxaban / Paracetamol","otherNames":["with Ivermectin"]},{"name":"Azithromycin / Ribaroxaban / Paracetamol","otherNames":["without Ivermectin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients Eligible for Family Medicine Unit No.20 and Family Medicine Unit No.13 belonging to the North DF of the IMSS.\n* Male and female patients\n* Patients over 18 years of age.\n* Patients with compliance with the operational definition COVID-19 and confirmatory test of P.C.R. positive within the first days of the illness (that are evaluated in first level of medical attention).\n* Patients with comorbidities such as Type 2 Diabetes Mellitus, Systemic Arterial Hypertension, Overweight or Obesity.\n* That they agree to sign an informed consent\n\n  \\- Related to Video Call:\n* That the Family Medicine Unit No.20 and the Family Medicine Unit No.13 belonging to the North DF of the IMSS have the Installation of Electronic Equipment for Internet use\n\nExclusion Criteria:\n\n* Severe COVID-19 patients (Ameriten sent immediately to second level of care, hospital) Patients with any Personal Pathological History of Hematological Diseases. â€¢ Patients allergic to macrolides (Azithromycin) and Ivermectin.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.","description":"Statistical differences were evaluated using Student's t test for quantitative variables. In relation to the presence of the number of days with clinical symptoms of COVID-19 by double therapy vs. triple therapy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"5.4"},{"groupId":"OG001","value":"7","spread":"5.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"3.4"},{"groupId":"OG001","value":"2","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"5.2"},{"groupId":"OG001","value":"5","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"4.8"},{"groupId":"OG001","value":"3","spread":"4.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"4.8"},{"groupId":"OG001","value":"5","spread":"5.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"4"},{"groupId":"OG001","value":"1","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"5.6"},{"groupId":"OG001","value":"5","spread":"5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"5.8"},{"groupId":"OG001","value":"6","spread":"5.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"4.1"},{"groupId":"OG001","value":"1","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"5.6"},{"groupId":"OG001","value":"4","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"4.1"},{"groupId":"OG001","value":"2","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"3.3"},{"groupId":"OG001","value":"2","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"3.1"},{"groupId":"OG001","value":"5","spread":"3.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"2.7"},{"groupId":"OG001","value":"3","spread":"2.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":"1.9"},{"groupId":"OG001","value":"4","spread":"1.6"}]}]}]},{"type":"PRIMARY","title":"Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS","description":"Statistical differences between clinical evolution vs therapeutic failure by type of treatment were evaluated using Pearson's Chi-square test as categorical variables.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Average Days of COVID-19 Symptoms Under Treatment of Early Intervention Due to Outcome in UMF 13 and 20 of the IMSS","description":"Statistical differences were evaluated using Student's t test for quantitative variables. The average duration of days with clinical symptoms of COVID-19 under early intervention treatment by outcome in the improvement of the modification of the clinical evolution of symptoms vs. therapeutic failure.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"5.6"},{"groupId":"OG001","value":"4","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"3.3"},{"groupId":"OG001","value":"1","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"5"},{"groupId":"OG001","value":"2","spread":"2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":"4.6"},{"groupId":"OG001","value":"1","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"5.2"},{"groupId":"OG001","value":"2","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"3.2"},{"groupId":"OG001","value":"1","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"5.4"},{"groupId":"OG001","value":"5","spread":"2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"6"},{"groupId":"OG001","value":"2","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"3.6"},{"groupId":"OG001","value":"1","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":"5.2"},{"groupId":"OG001","value":"1","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"4.1"},{"groupId":"OG001","value":"3","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"3.5"},{"groupId":"OG001","value":"3","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"3.3"},{"groupId":"OG001","value":"2","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"2.6"},{"groupId":"OG001","value":"2","spread":"1.2"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Were Alive and Had COVID-19 Symptoms by Type of Therapy During a 14-day Follow-up","description":"Survival analysis. The time it takes for 50% of COVID-19 patients to improve symptoms during a 14-day follow-up with dual therapy vs. triple therapy","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["asthenia","Nausea","Tinnitus","Palpitations","Ecchymosis"]}}}